|
hr HPV status
|
All women n = 515 (%)
|
HIV positive n = 220 (%)
|
HIV negative n = 295 (%)
|
OR (95% CI)
|
|---|
|
Crude
|
Adjusteda
|
|---|
|
HR HPV negative
|
414 (80.4)
|
166 (75.4)
|
248 (84.1)
|
1 (ref)
|
1 (ref)
|
|
HR HPV positive
|
101 (19.6)
|
54 (24.6)
|
47 (15.9)
|
1.9 (1.2–2.9)
|
1.7 (1.1-3.1)
|
|
HPV 16
|
20 (3.9)
|
14 (5.4)
|
6 (2.6)
|
3.3 (1.1-9.7)
|
3.1 (1.3-6.3)
|
|
HPV 18
|
12 (2.3)
|
3 (1.4)
|
9 (3.10
|
0.4 (0.1-1.8)
|
0.4 (0.2-1.9)
|
|
HPV 31
|
17 (3.3)
|
12 (5.5)
|
5 (1.7)
|
3.1 (1.1-11.1)
|
1.9 (0.9-8.1)
|
|
HPV 33
|
2 (0.4)
|
1 (0.5)
|
1 (0.3)
|
1.3 (0.0-49.3
|
1.1 (0.0-46.1)
|
|
HPV 35
|
18 (3.5)
|
13 (5.9)
|
5 (1.7)
|
3.4 (1.2-11.9)
|
3.6 (1.4-6.9)
|
|
HPV 39
|
3 (0.6)
|
1 (0.5)
|
2 (0.7)
|
0.7 (0.1-9.4)
|
0.6 (0.2-9.1)
|
|
HPV 45
|
7 (1.4)
|
3 (1.4)
|
4 (1.4)
|
1.0 (0.2-5.4)
|
0.9 (0.1-5.9)
|
|
HPV 51
|
10 (1.9)
|
5 (2.3)
|
5 (1.7)
|
1.4 (0.3-5.4
|
1.4 (0.4-5.5)
|
|
HPV 52
|
12 (2.3)
|
6 (2.7)
|
6 (2.0)
|
1.4 (0.4-4.8)
|
1.3 (0.2-5.1)
|
|
HPV 56
|
6 (1.2)
|
2 (0.9)
|
4 (1.4)
|
0.7 (0.1-4.3)
|
0.7 (0.2-6.9)
|
|
HPV 58
|
18 (3.5)
|
9 (4.1)
|
9 (3.5)
|
1.4 (0.5-3.9)
|
1.2 (0.3-4.1)
|
|
HPV 59
|
3 (0.6)
|
1 (0.5)
|
2 (0.7)
|
0.7 (0.02-9.4)
|
0.5 (0.1-10.1)
|
|
HPV 68
|
4 (0.8)
|
1 (0.5)
|
3 (1.0)
|
0.4 (0.02-4.8)
|
0.4 (0.1-6.1)
|
|
Multiple HPV infection
|
28 (5.4)
|
18 (8.2)
|
10 (3.9)
|
2.5 (1.1-6.1)
|
2.6 (1.3-5.3)
|
- aadjusted for confounders of age, antiretroviral drug use and number of life time sexual partners.
